禁止
发表于 2025-3-27 00:10:54
http://reply.papertrans.cn/47/4623/462297/462297_31.png
Condescending
发表于 2025-3-27 01:37:04
http://reply.papertrans.cn/47/4623/462297/462297_32.png
有组织
发表于 2025-3-27 08:20:42
http://reply.papertrans.cn/47/4623/462297/462297_33.png
choroid
发表于 2025-3-27 12:17:47
Skin Reactions to Immune Checkpoint Inhibitors,patients, 43.5% have a cutaneous AE, and, at our institution, 20% of them had a dose interruption as a result. This means potentially 9% of patients have dose interruption of ipilimumab because of their cutaneous AEs. In the following chapter, we review the categories of these drugs, common cutaneous effects, their grading, and management options.
AORTA
发表于 2025-3-27 17:00:47
Immune-Related Oral, Otologic, and Ocular Adverse Events,onal chemotherapy are well known, the toxicity profile of emerging immune therapies is not fully elucidated. They have been associated with atypical side effects labeled collectively as immune-related adverse events (irAEs).
POWER
发表于 2025-3-27 17:56:08
http://reply.papertrans.cn/47/4623/462297/462297_36.png
Tailor
发表于 2025-3-28 02:00:30
0065-2598 me the challenges associated with immunotherapy.Presents cut.The field of immuno-oncology continues to rapidly evolve as new insights to fight and treat cancer emerge. The fourth edition of .Immunotherapy. provides the most current overview of immuno-oncology in different cancer types and toxicities
吃掉
发表于 2025-3-28 06:06:30
The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl
miniature
发表于 2025-3-28 09:42:41
http://reply.papertrans.cn/47/4623/462297/462297_39.png
欺骗手段
发表于 2025-3-28 10:45:02
http://reply.papertrans.cn/47/4623/462297/462297_40.png